Press Releases

Synthetic Biologics to Report Second Quarter 2016 Operational Highlights and Financial Results on August 3, 2016

-- Conference Call Scheduled for Wednesday, August 3, 2016 at 4:30 p.m. EDT --

ROCKVILLE, Md., July 26, 2016 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its operational highlights and financial results for the three and six months ending June 30, 2016, on Wednesday, August 3, 2016, and to host a conference call the same day at 4:30 p.m. EDT.

Synthetic Biologics, Inc. www.syntheticbiologics.com

 

The dial-in information for the call is as follows:

U.S. (toll free):

1-888-347-5280

International:

+1 412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/16339. An archive of the call will be available for approximately 90 days at the same URL, https://www.webcaster4.com/Webcast/Page/1096/16339, beginning approximately one hour after the call's conclusion.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea (AAD) and the emergence of antibiotic-resistant organisms. The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-second-quarter-2016-operational-highlights-and-financial-results-on-august-3-2016-300303745.html

SOURCE Synthetic Biologics, Inc.